GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2025.
GeneDx (NASDAQ:WGS) reported fourth-quarter revenue of $121 million, bringing full-year 2025 revenue to $428 million, as ...
We came across a bullish thesis on GeneDx Holdings Corp. on Danny’s Substack by Danny Green. In this article, we will ...
Q4 2025 earnings call recap: revenue growth, 2026 guidance, margins, sales force expansion & reimbursement risks—read key insights now.
Chennai: One in four Indian breast cancer patients carries inherited genetic variants that raise cancer risk beyond the commonly tested BRCA1 and BRCA.
Expecting Growth in 2026 Families are not just receiving results - they are gaining the confidence and capability to ...
Polen Capital, an investment management company, released its fourth-quarter investor letter for “Polen 5Perspectives Small ...
Company’s exhibit theater presentation will highlight multiomic and multimodal innovations in rare disease diagnostics ...
A study reveals 1 in 4 Indian breast cancer patients carry inherited genetic variants beyond known BRCA genes, urging broader testing strategies.
For full year 2026, GeneDx reaffirmed guidance of $540 million to $555 million in revenue, with the midpoint of $547.5 million slightly above the analyst consensus of $543 million. The company expects ...
Caris Life Sciences, Inc. (NASDAQ:CAI) is one of the Best All-Time Low Stocks to Invest In Now. On February 24, Caris Life ...
The addition of PacBio to the iHope network will further expand diagnostic access worldwide DAMASCUS, MD, UNITED ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results